Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-marketing safety study of 23-valent pneumococcal polysaccharide vaccine in a large population
CTR20243701Phase 4Active
- Sponsor
- Zhifei Green Bamboo
- Start
- Oct 2024
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of 23-valent pneumococcal polysaccharide vaccine in Pneumococcal pneumonia (PP), pneumococcal meningitis, acute otitis media (AOM), pneumococcal bacteremia, sponsored by Zhifei Green Bamboo. Started Oct 2024; status: active.
02
Drugs
23-valent pneumococcal polysaccharide vaccine
03
Conditions
Pneumococcal pneumonia (PP)pneumococcal meningitisacute otitis media (AOM)pneumococcal bacteremia
Beyond the preview
Go deeper on CTR20243701.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243701.